Accel-Sevelamer · DIN 02461501 · 800 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Lanthanum
Brand(s): Fosrenol and Generics
DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet
Sevelamer Hydrochloride
Brand(s): Renagel
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Accel-Sevelamer
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Renvela
DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder
sachet
Updated: June 7, 2021
i) For the treatment of hyperphosphatemia associated with end-stage renal disease
(ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8
mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR
ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate
levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery
calcification.
466
Notes:
1. Calcium and phosphate levels provided to demonstrate sustained elevations should be
at least 4 weeks apart.
2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but
who experience adjusted serum calcium > 2.65 mmol/L must provide supporting
laboratory levels before treatment and while on treatment and should include the
dose(s) of calcium-based binder used.
Exclusion Criteria:
Sevelamer will not be reimbursed in the following cases:
Use in combination therapy with another funded non-calcium-based phosphate binder
(e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer
formulations)
Duration of approval: lifetime
On a case-by-case basis, requests may be considered for sevelamer under the EAP for a
patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65
mmol/L.
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 305, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Accel-Sevelamer · DIN 02461501
Manufacturer: Accel Pharma Inc.; listing date 2021-06-07
Health Canada: Marketed since 2017-11-08 · brand ACCEL-SEVELAMER · ATC V03AE02 SEVELAMER · form Tablet · route Oral · ingredients SEVELAMER CARBONATE 800 MG · company Accel pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAccel-Sevelamer: Formulary list price $1.26 per unit (the source does not state the unit; exact figure $1.2634). What the ministry pays, not the patient.
Ministry pays: $1.2634 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02461501)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02461501).
DIN 02461501: Accel-Sevelamer
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 401800009; group id 552; item number 1488; lccId None; manufacturer id ACC
Source form: Tab; strength: 800mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.2634; ministry $1.2634
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461501
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94913
Interchangeable products
Renvela · DIN 02354586 · $1.2634
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461501
Shortage record checked October 6, 2026